Active Tuberculosis in Patients with Psoriasis Receiving Biologic Therapy: A Systematic Review
Biologic therapies pose a risk for opportunistic infections, especially for reactivating latent tuberculosis infection (LTBI).
The aim was to describe the clinical features and mortality rate of active Mycobacterium tuberculosis (TB) in psoriasis patients receiving biologic therapies.
A systematic review of PubMed, Google Scholar, ScienceDirect, Cochrane Library, and ClinicalTrials.gov databases was performed. Studies describing active TB in patients with psoriasis receiving biologic therapy from inception to May 31, 2018 were included. Clinical data as well as mortality rates were recorded.
Fifty-one studies were included, evaluating 78 patients with active TB: 11 prospective studies, 13 retrospective, and 27 case reports/series. Most patients (73%) with active TB were male, the mean age was 48 ± 13 years, and 85% were of European or Asian origin. Pre-treatment LTBI screening was negative for 63% of patients. Disease presented in 33% of patients within the first 3 months of treatment, and in 51% within the first 6 months. Most patients (72%) presented with extra-pulmonary TB, and 49% had disseminated disease. The mortality rate was 7%.
Limitations of this review are its small sample size and inclusion of case reports.
Some patients develop active TB despite LTBI screening. Clinicians initiating biologic therapy in patients with psoriasis should be aware of the clinical features of active TB in this scenario.
We would like to acknowledge the help of Dr. Debby Mir in writing the manuscript.
Compliance with Ethical Standards
The data have not been previously presented.
No funding was received for this study.
Conflict of interest
IS, EB, ESC, TA, DS, EH and LP report no conflict of interest.
- 4.Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009;60:1884–94.CrossRefGoogle Scholar
- 7.Rodríguez-Jiménez P, Mir-Viladrich I, Chicharro P, Solano-López G, López-Longo FJ, Taxonera C, et al. Prevention and treatment of tuberculosis infection in candidates for biologic therapy: a multidisciplinary consensus statement adapted to the dermatology patient. Actas Dermosifiliogr. 2018;109:584–601.CrossRefGoogle Scholar
- 10.Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med. 2000;161:1376–95.Google Scholar
- 11.WHO estimates of tuberculosis incidence by country 2014 v2.pdf [Internet]. [cited 2019 Jan 30]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/491527/WHO_estimates_of_tuberculosis_incidence_by_country__2014_v2.pdf.
- 14.Baeten D, Kruithof E, Van den Bosch F, Van den Bossche N, Herssens A, Mielants H, et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis. 2003;62:829–34.CrossRefGoogle Scholar
- 16.Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis. 2006;10:1127–32.Google Scholar
- 17.Laffitte E, Janssens JP, Roux-Lombard P, Thielen AM, Barde C, Marazza G, et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test. Br J Dermatol. 2009;161:797–800.CrossRefGoogle Scholar
- 18.Kitamura G, Mehr N, Anderson N, Sirichotiratana M. A case of tuberculosis in a patient on efalizumab and etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis. Dermatol Online J. 2009;15:11.Google Scholar
- 23.Chiu H-Y, Hsueh P-R, Tsai T-F. Clinical experience of QuantiFERON(®)-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan. Br J Dermatol. 2011;164:553–9.Google Scholar
- 25.Skroza N, Proietti I, Bernardini N, La Viola G, Nicolucci F, Tolino E, et al. Severe psoriasis with positive tuberculosis test and treatment with biologic therapy: a case report. Cutis. 2012;90:120–2.Google Scholar
- 30.Letada PR, Hitchcock E, Steele SL, Winstanley D. Transient improvement in chronic psoriasis after treatment of TNF-α blocker induced disseminated M. tuberculosis infection. J Drugs Dermatol. 2012;11:119–20.Google Scholar
- 31.Yang H-Z, Wang K, Jin H-Z, Gao T-W, Xiao S-X, Xu J-H, et al. Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial. Chin Med J (Engl). 2012;125:1845–51.Google Scholar
- 37.Reich K, Wozel G, Zheng H, van Hoogstraten HJF, Flint L, Barker J. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). Br J Dermatol. 2013;168:1325–34.CrossRefGoogle Scholar
- 38.Hsia EC, Cush JJ, Matteson EL, Beutler A, Doyle MK, Hsu B, et al. Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials. Arthritis Care Res. 2013;65:309–13.CrossRefGoogle Scholar
- 39.Sánchez-Moya AI, García-Doval I, Carretero G, Sánchez-Carazo J, Ferrandiz C, Herrera Ceballos E, et al. Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain. BIOBADADERM registry. J Eur Acad Dermatol Venereol. 2013;27:1366–74.CrossRefGoogle Scholar
- 41.Luquín N, Masiá M, Noguera R, Gutiérrez F. Anal tuberculosis complicating anti-TNFα therapy. BMJ Case Rep. 2014;2014.Google Scholar
- 42.Errichetti E, Piccirillo A. Latent tuberculosis reactivation in a patient with erythrodermic psoriasis under treatment with ustekinumab and a low dose steroid, despite isoniazid chemoprophylaxis. Eur J Dermatol. 2014;24:508–9.Google Scholar
- 44.Mariette X, Vencovsky J, Lortholary O, Gomez-Reino J, de Longueville M, Ralston P, et al. The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region. RMD Open. 2015;1:e000044.CrossRefGoogle Scholar
- 48.Gilbert KEGE, Manalo IF, Wu JJ. Active tuberculosis in a psoriasis patient treated with tumor necrosis factor inhibitors despite an initial negative tuberculin skin test and no known risk factors. Dermatol Online J. 2016;22.Google Scholar
- 53.Conti A, Piaserico S, Gisondi P, Odorici G, Galdo G, Lasagni C, et al. Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting. Dermatol Ther. 2017;30.Google Scholar
- 55.Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76:418–31.CrossRefGoogle Scholar
- 56.Giollo A, Carletto A, Tonetta S, Del Bravo P, Rossini M. Tuberculosis infection despite isoniazid prophylaxis in a patient with psoriatic arthritis treated with etanercept. J Clin Rheumatol. 2017.Google Scholar
- 57.Huang T-H, Wei Y-C, Lan C-CE. QuantiFERON®-TB Gold test conversion in a psoriatic patient with pleural tuberculosis one year after adalimumab treatment. Kaohsiung J Med Sci. 2018;34:179–80.Google Scholar
- 60.Mandy Chan WM, Oon HH, Chong W-S. Clinical experience of adalimumab in the treatment of psoriasis—a 10-year journey in a tertiary dermatology centre. Indian J Dermatol Venereol Leprol. 2018;84:205–8.Google Scholar
- 63.Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents against tumor necrosis factor-alpha–California 2002–2003. MMWR Morb Mortal Wkly Rep. 2004;53:683–6.Google Scholar
- 69.Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Extended report: drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69:522.CrossRefGoogle Scholar
- 72.Harris J, Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol. 2010;161:1–9.Google Scholar
- 74.Romiti R, Valenzuela F, Chouela EN, Xu W, Pangallo B, Moriarty SR, et al. Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis. Br J Dermatol. 2019.Google Scholar